Recursion Pharmaceuticals, Inc. is rated a Sell due to cash burn, Q3 net loss of $162.25M and operational trends. Learn more ...

Equity Insider News Commentary ? November's wave of FDA oncology approvals signals the industry's shift toward platform-based precision therapies over broad-spectrum approaches[1]. The global ...

Valinor, a pioneering AI company leveraging advanced machine learning models to increase the probability of clinical trial success by deeply understanding patient response, today announced $13 million ...

PsiThera, formerly Psivant Therapeutics, raised just over $47 million for oral drugs targeting “diseases long-constrained by ...

Munich from 24–27 March 2026, with sustainability firmly in the spotlight. The focus on the Green Lab will run through the trade fair, conference, and supporting program, showcasing innovations that ...

Viewed this way, a definition is a decision mechanism. It distinguishes some elements of the universe from the others. Hence ...